EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin

Oluwadolapo D Lawal, Herbert D Aronow, Fisayomi Shobayo, Yichi Zhang, Anne L Hume, Tracey H Taveira, Kelly L Matson, Justin Gold iD, Xuerong Wen iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-10 · 45 (10) · 638-653

DOI: 10.1002/phar.70055 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 25.08.2025. Verfasst von Oluwadolapo D Lawal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Gastrointestinal Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are sparse data to guide resumption of direct oral anticoagulants (DOACs) versus warfarin in patients with atrial fibrillation (AF) who survive a major gastrointestinal bleeding (GIB) event.

Objective

To compare the risk–benefit profile of restarting DOACs versus warfarin among patients with AF following hospitalization for major GIB.

Methods

Using claims submitted to a commercial health insurance database from January 2010 to December 2017, we identified adult patients with AF hospitalized for a major GIB while receiving oral anticoagulants. Eligible patients were required to have survived and restarted oral anticoagulation with DOACs or warfarin within 90 days following hospital discharge for major GIB. The outcomes of interest were subsequent hospitalization for major bleeding, hospitalization for ischemic stroke/systemic embolism (SE), all‐cause mortality, and net adverse clinical effect (NACE), which was a composite of all‐cause mortality, hospitalization for ischemic stroke/SE, and hospitalization for major bleeding. Stabilized inverse probability of treatment weighting was used to balance measured covariates.

Results

Overall, 4,389 patients resumed oral anticoagulation, with 3016 (68.7%) on warfarin and 1373 (31.3%) on DOACs, within 90 days of hospital discharge for major GIB. The median (interquartile range) time from hospital discharge for major GIB to resumption of oral anticoagulant was 24 (10, 47) days. The weighted hazards ratio (HR) among individuals that resumed DOACs versus warfarin after major GIB was 0.76 (95% confidence interval, CI: 0.60, 0.96) for subsequent hospitalization for major bleeding, 0.91 (95% CI: 0.53, 1.55) for subsequent hospitalization for ischemic stroke/SE, and 0.83 (95% CI: 0.72, 0.97) for NACE.

Conclusions

Among patients with AF who survived and resumed oral anticoagulation within the first 90 days after hospitalization for a major GIB event, restarting oral anticoagulation treatment with DOACs was associated with a lower risk of subsequent hospitalization for major bleeding and the composite outcome of ischemic stroke, SE, all‐cause mortality, and recurrent or incident major bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationWarfarinGastrointestinal HemorrhageAnticoagulantsHumansFemaleMaleAgedAdministration, OralMiddle AgedHospitalizationAged, 80 and overRetrospective StudiesStrokeTreatment Outcome

Stichwörter der Autor:innen

atrial fibrillationdirect oral anticoagulantmajor bleedingwarfarin

Substanzen

WarfarinAnticoagulants

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
  • Lifespan, Cardiovascular Institute, Providence, Rhode Island, USA.
  • Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Department of Cardiology, University of Texas Health Science Center, Houston, Texas, USA.
  • Department of Computer Sciences and Statistics, University of Rhode Island, Kingston, Rhode Island, USA.
  • Providence Veterans Affairs, Medical Center, Providence, Rhode Island, USA.

ORCID-Profile: Justin Gold, Xuerong Wen

Zitieren

APA

Lawal, O. D., Aronow, H. D., Shobayo, F., Zhang, Y., Hume, A. L., Taveira, T. H., Matson, K. L., Gold, J., & Wen, X. (2025). Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(10), 638-653. https://doi.org/10.1002/phar.70055

Vancouver

Lawal OD, Aronow HD, Shobayo F, Zhang Y, Hume AL, Taveira TH, et al. Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(10):638-653. doi:10.1002/phar.70055

BibTeX
@article{Lawal2025,
  author = {Lawal, Oluwadolapo D and Aronow, Herbert D and Shobayo, Fisayomi and Zhang, Yichi and Hume, Anne L and Taveira, Tracey H and Matson, Kelly L and Gold, Justin and Wen, Xuerong},
  title = {Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {10},
  pages = {638--653},
  doi = {10.1002/phar.70055}
}
Kostenlos starten →